•
KU
KURA
Kura Oncology, Inc.
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
758.79M
Volume
1.23M
52W High
$12.49
52W Low
$5.41
Open
$0.00
Prev Close
$8.60
Day Range
0.00 - 0.00
About Kura Oncology, Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Latest News
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Benzinga•Dec 4
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.•Nov 25
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
GlobeNewswire Inc.•Oct 18
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications
GlobeNewswire Inc.•Oct 10
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga•Sep 29
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
Benzinga•Sep 25
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
GlobeNewswire Inc.•Jun 2
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
GlobeNewswire Inc.•Jun 1